Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
Does admission acetylsalicylic acid uptake in hospitalized COVID-19 patients have a protective role? Data from the Spanish SEMI-COVID-19 Registry
Internal and Emergency Medicine, Volume 17, No. 3, Year 2022
Notification
URL copied to clipboard!
Description
Acetylsalicylic acid (ASA) is widely used in the treatment and prevention of cardiovascular disorders. Our objective is to evaluate its possible protective role, not only in mortality but also in other aspects such as inflammation, symptomatic thrombosis, and intensive care unit (ICU) admission in hospitalized COVID-19 patients. We realized an observational retrospective cohort study of 20,641 patients with COVID-19 pneumonia collected and followed-up from Mar 1st, 2020 to May 1st, 2021, from the nationwide Spanish SEMI-COVID-19 Registry. Propensity score matching (PSM) was performed to determine whether treatment with ASA affected outcomes in COVID-19 patients. On hospital admission, 3291 (15.9%) patients were receiving ASA. After PSM, 3291 patients exposed to ASA and 2885 not-exposed patients were analyzed. In-hospital mortality was higher in the ASA group (30.4 vs. 16.9%, p < 0.001) in the global sample. After PSM, no differences were found between groups (30.4 vs. 30.3%, p = 0.938). There were no differences in inflammation, symptomatic thrombosis, or ICU admission. In conclusion, ASA intake is not associated with in-hospital mortality or any other health outcome evaluated after applying PSM analysis in a real-world large sample of hospitalized COVID-19 patients. © 2021, Società Italiana di Medicina Interna (SIMI).
Authors & Co-Authors
Méndez-Bailón, Manuel
Spain, Madrid
Hospital Clínico San Carlos
Gómez-Huelgas, Ricardo
Spain, Malaga
Universidad de Málaga
Ramos-Rincón, José Manuel
Spain, Elche
Universidad Miguel Hernández de Elche
Lumbreras, Carlos
Unknown Affiliation
Homs, Narcís A.
Unknown Affiliation
De-Miguel-Campo, Borja
Unknown Affiliation
Lora-Tamayo, Jaime
Unknown Affiliation
Maestro-de la Calle, Guillermo
Unknown Affiliation
Fernández, Marcos Sánchez
Unknown Affiliation
Martínez, Luis
Unknown Affiliation
Calvo, Cristina Marcelo
Unknown Affiliation
Robles, Elena Martínez
Unknown Affiliation
Estrada, Vicente P.
Unknown Affiliation
Moreno-Torres, Victor
Unknown Affiliation
Vazquez, M. J.
Unknown Affiliation
Cervera, Carlos García
Unknown Affiliation
Wikman-Jorgensen, Philip Erik
Unknown Affiliation
Fernàndez, Javier C.
Unknown Affiliation
Bernabeu-Wittel, Máximo
Unknown Affiliation
Villar, Jesús Manuel Fernández
Unknown Affiliation
Statistics
Citations: 5
Authors: 20
Affiliations: 14
Identifiers
Doi:
10.1007/s11739-021-02870-1
ISSN:
18280447
Research Areas
Covid
Health System And Policy
Noncommunicable Diseases
Study Design
Cohort Study
Case-Control Study
Study Approach
Quantitative